Sujatha Nallapareddy

Oncology

1700 S Potomac St
Aurora, CO 80012

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Real-world clinical characteristics and outcomes of patients with locally advanced, unresectable esophageal/gastroesophageal junction cancer treated with definitive chemoradiotherapy in the United States community oncology setting.

Real-world clinical characteristics and outcomes of patients with locally advanced, unresectable esophageal/gastroesophageal junction cancer treated with definitive chemoradiotherapy in the United States community oncology setting.

Journal: Frontiers in oncology

Published: August 04, 2025

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Journal: The Lancet. Oncology

Published: July 19, 2012

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.

Journal: Cancer medicine

Published: June 04, 2012

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 17, 2011

Showing 1-4 of 4

Last Updated: 09/26/2026